102 related articles for article (PubMed ID: 7904248)
21. Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells.
Busso N; Masur SK; Lazega D; Waxman S; Ossowski L
J Cell Biol; 1994 Jul; 126(1):259-70. PubMed ID: 7517943
[TBL] [Abstract][Full Text] [Related]
22. Urokinase-type plasminogen activator/type-2 plasminogen-activator inhibitor complexes are not internalized upon binding to the urokinase-type-plasminogen-activator receptor in THP-1 cells. Interaction of urokinase-type plasminogen activator/type-2 plasminogen-activator inhibitor complexes with the cell surface.
Ragno P; Montuori N; Rossi G
Eur J Biochem; 1995 Oct; 233(2):514-9. PubMed ID: 7588796
[TBL] [Abstract][Full Text] [Related]
23. Characterization of the cellular binding site for the urokinase-type plasminogen activator.
Estreicher A; Wohlwend A; Belin D; Schleuning WD; Vassalli JD
J Biol Chem; 1989 Jan; 264(2):1180-9. PubMed ID: 2536017
[TBL] [Abstract][Full Text] [Related]
24. Initiation of plasminogen activation on the surface of monocytes expressing the type II transmembrane serine protease matriptase.
Kilpatrick LM; Harris RL; Owen KA; Bass R; Ghorayeb C; Bar-Or A; Ellis V
Blood; 2006 Oct; 108(8):2616-23. PubMed ID: 16794252
[TBL] [Abstract][Full Text] [Related]
25. Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA). Inhibition of proliferation and invasion of human ovarian cancer cells.
Wilhelm O; Weidle U; Höhl S; Rettenberger P; Schmitt M; Graeff H
FEBS Lett; 1994 Jan; 337(2):131-4. PubMed ID: 8287966
[TBL] [Abstract][Full Text] [Related]
26. Urokinase-mediated posttranscriptional regulation of urokinase-receptor expression in non small cell lung carcinoma.
Montuori N; Mattiello A; Mancini A; Taglialatela P; Caputi M; Rossi G; Ragno P
Int J Cancer; 2003 Jun; 105(3):353-60. PubMed ID: 12704669
[TBL] [Abstract][Full Text] [Related]
27. Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels.
Del Vecchio S; Stoppelli MP; Carriero MV; Fonti R; Massa O; Li PY; Botti G; Cerra M; D'Aiuto G; Esposito G
Cancer Res; 1993 Jul; 53(13):3198-206. PubMed ID: 7686450
[TBL] [Abstract][Full Text] [Related]
28. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
[TBL] [Abstract][Full Text] [Related]
29. Distribution and lateral mobility of the urokinase-receptor complex at the cell surface.
Myöhänen HT; Stephens RW; Hedman K; Tapiovaara H; Rønne E; Høyer-Hansen G; Danø K; Vaheri A
J Histochem Cytochem; 1993 Sep; 41(9):1291-301. PubMed ID: 8394852
[TBL] [Abstract][Full Text] [Related]
30. Discrimination of different forms of the murine urokinase plasminogen activator receptor on the cell surface using monoclonal antibodies.
Rasch MG; Pass J; Illemann M; Høyer-Hansen G; Lund IK
J Immunol Methods; 2008 Nov; 339(1):55-65. PubMed ID: 18761343
[TBL] [Abstract][Full Text] [Related]
31. uPA-silica-Particles (SP-uPA): a novel analytical system to investigate uPA-uPAR interaction and to test synthetic uPAR antagonists as potential cancer therapeutics.
Guthaus E; Bürgle M; Schmiedeberg N; Hocke S; Eickler A; Kramer MD; Sweep CG; Magdolen V; Kessler H; Schmitt M
Biol Chem; 2002 Jan; 383(1):207-16. PubMed ID: 11930939
[TBL] [Abstract][Full Text] [Related]
32. Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor.
Ploug M; Ellis V; Danø K
Biochemistry; 1994 Aug; 33(30):8991-7. PubMed ID: 8043585
[TBL] [Abstract][Full Text] [Related]
33. Urokinase induces proliferation of human ovarian cancer cells: characterization of structural elements required for growth factor function.
Fischer K; Lutz V; Wilhelm O; Schmitt M; Graeff H; Heiss P; Nishiguchi T; Harbeck N; Kessler H; Luther T; Magdolen V; Reuning U
FEBS Lett; 1998 Oct; 438(1-2):101-5. PubMed ID: 9821967
[TBL] [Abstract][Full Text] [Related]
34. Caveolin-1 mediates the expression and localization of cathepsin B, pro-urokinase plasminogen activator and their cell-surface receptors in human colorectal carcinoma cells.
Cavallo-Medved D; Mai J; Dosescu J; Sameni M; Sloane BF
J Cell Sci; 2005 Apr; 118(Pt 7):1493-503. PubMed ID: 15769846
[TBL] [Abstract][Full Text] [Related]
35. Urokinase receptor in human malignant mesothelioma cells: role in tumor cell mitogenesis and proteolysis.
Shetty S; Kumar A; Johnson A; Pueblitz S; Idell S
Am J Physiol; 1995 Jun; 268(6 Pt 1):L972-82. PubMed ID: 7611439
[TBL] [Abstract][Full Text] [Related]
36. The urokinase-type plasminogen activator receptor, a GPI-linked protein, is localized in caveolae.
Stahl A; Mueller BM
J Cell Biol; 1995 Apr; 129(2):335-44. PubMed ID: 7721938
[TBL] [Abstract][Full Text] [Related]
37. Processing of complex between urokinase and its type-2 inhibitor on the cell surface. A possible regulatory mechanism of urokinase activity.
Ragno P; Montuori N; Vassalli JD; Rossi G
FEBS Lett; 1993 Jun; 323(3):279-84. PubMed ID: 8388810
[TBL] [Abstract][Full Text] [Related]
38. The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation.
Behrendt N; List K; Andreasen PA; Danø K
Biochem J; 2003 Apr; 371(Pt 2):277-87. PubMed ID: 12534347
[TBL] [Abstract][Full Text] [Related]
39. Urokinase/urokinase receptor system: internalization/degradation of urokinase-serpin complexes: mechanism and regulation.
Conese M; Blasi F
Biol Chem Hoppe Seyler; 1995 Mar; 376(3):143-55. PubMed ID: 7612191
[TBL] [Abstract][Full Text] [Related]
40. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
Costantini V; Sidoni A; Deveglia R; Cazzato OA; Bellezza G; Ferri I; Bucciarelli E; Nenci GG
Cancer; 1996 Mar; 77(6):1079-88. PubMed ID: 8635127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
